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SUMMARY 
Accumulation of p53 protein was determined by immunohistochemistry in archival material of biopsy specimens 
from 102 patients with Barrett’s oesophagus with different grades of dysplasia, in 24 oesophageal adenocarcinomas 
associated with Barrett’s oesophagus, and in 23 cases of metaplastic epithelium adjacent to these carcinomas. 
Immunostaining for the p53 protein was found in 23/102 (23 per cent) cases of the Barrett’s oesophagus biopsies and 
in 12/23 (52 per cent) cases of Barrett’s oesophagus adjacent to adenocarcinoma. Significant correlations were found 
between the grade of dysplasia and p53 immunoreactivity in both Barrett’s biopsies without adenocarcinoma 
(P<O.OOl) and Barrett’s oesophagus adjacent to adenocarcinoma (PC0.05). In the adenocarcinomas, intense nuclear 
immunohistochemical staining for p53 was diffusely or focally present in 20/24 (83 per cent) of the specimens. In 
Barrett’s oesophagus, p53 is a progression marker with high expression in high-grade dysplasia (89 per cent) and 
adenocarcinoma (83 per cent). 
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INTRODUCTION 
In Barrett’s oesophagus, the stratified squamous 
epithelium of the distal oesophagus is replaced 
by metaplastic columnar epithelium. 1,2 Patients 
with Barrett’s oesophagus have a 30 to 40-fold 
increased risk of developing oesophageal adeno- 
c a r c i n ~ m a . ~ ? ~  Although adenocarcinoma in 
Barrett’s oesophagus is preceded by epithelial dys- 
plasia, the time course of progression of simple 
metaplasia into dysplastic Barrett’s epithelium and 
ultimately into infiltrating adenocarcinoma is 
unknown. Furthermore, grading of dysplasia is to 
a certain extent subjective, leading to significant 
inter-observer variation. Consequently, there is 
insufficient consensus as to the optimal treatment 
of these patients. Objective prognostic criteria 
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predicting which cases of Barrett’s epithelium 
will progress towards malignancy are therefore 
of major importance. Previous immunohisto- 
chemical studies with proliferation markers have 
already shown higher proliferation rates in dys- 
plastic Barrett’s epithelium5 and abnormalities 
measured by DNA flow cytometry may precede 
malignancy.6 
During the past few years, interest in tumour 
suppressor genes and proteins in (pre)malignant 
lesions has intensified. The appearance of the p53 
tumour suppressor protein has been reported in a 
wide variety of malignant and premalignant 
p53 immunoreactivity has been 
reported in 62-87 per cent of oesophageal adeno- 
carcinomas, and in non-dysplastic and dysplastic 
Barrett’s oesophagus. ”-’* 
The aim of the present study was to determine 
whether immunohistochemically-detectable p53 
protein accumulation occurs along with the 
development of dysplasia in Barrett’s oesophagus. 
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MATERIALS AND METHODS 
Tissues 
p53 immunoreactivity was studied in archival 
biopsies taken between 1980 and 1992 from 102 
patients with Barrett’s oesophagus with various 
degrees of dysplasia but without adenocarcinoma. 
The number of biopsies per patient varied from 
one to 12. Furthermore, paraffin-embedded tissue 
blocks from 24 oesophagusscardia resection speci- 
mens with adenocarcinoma in Barrett’s oesopha- 
gus encountered between 1990 and 1992 were 
investigated. All patients had undergone cardiac- 
oesophageal resection with gastric tube interposi- 
tion. Surgery was performed at a mean age of 62 
years (range 45-80 years). None of the patients 
with adenocarcinoma had received chemo- or 
radiotherapy prior to surgery. One paraffin block 
containing adenocarcinoma was selected in each 
case. To determine the efficacy of p53 immuno- 
staining in paraffin-embedded tissues, immuno- 
histochemistry for the detection of p53 protein was 
performed on corresponding fresh frozen samples 
of 20 of the adenocarcinomas. Barrett’s epithelium 
adjacent to the tumour was found in 23 cases. In 
one case, Barrett’s oesophagus was diagnosed in 
biopsy specimens prior to oesophageal resection. 
Normal gastriwardiac mucosa was used for 
control purposes. 
Histopathological criteria 
The histological sections were reviewed by two 
pathologists (AHM and FTB). Tumour staging 
was performed according to pTNM criteria. 
Barrett’s oesophagus was defined as columnar 
epithelial lining of the oesophagus for at least 3 cm 
proximal to the gastro-oesophageal junction. All 
cases had specialized columnar-type metaplasia 
characterized by the presence of intestinal goblet 
cells. Dysplasia was graded into three categories 
following criteria revised by Reid et al.: l 9  negative; 
indefinite or low-grade dysplasia; and high-grade 
dysplasia. Slides were coded and scoring of p53 
immunoreactivity was performed independently of 
the grading of the sections. 
Immunohistochemistry 
Cryostat sections (5 pm) of fresh tissues were 
air-dried and fixed in acetone (-20°C). After 
blocking of endogenous peroxidase activity and 
rinsing in phosphate-buffered saline (PBS, pH 7.4), 
p53 protein labelling was performed by the 
standard peroxidaselanti-peroxidase method 
(Dakopatts Z 259; Sigma P 2416, St Louis, MO, 
U.S.A.). 
DO-7 (Dakopatts, Glostrup, Denmark), an Ig2b 
kappa monoclonal antibody recognizing an 
epitope in the N-terminus between amino acids 35 
and 45 of human p53 protein, was used on 
formalin-fixed, paraffin-embedded tissues. 
For paraffin sections, an antigen retrieval 
method was applied.20 After blocking of endogen- 
ous peroxidase, p53 labelling with DO-7 was 
performed by the streptavidin-biotin complex 
procedure. The sections were preincubated for 
15 min at 37°C with 10 per cent normal goat 
serum, diluted in PBS. DO-7, diluted 1/25 in 
PBS, was added for overnight incubation at 4°C. 
The negative controls were incubated with PBS 
only. The sections were subsequently incubated 
with biotinylated goat-anti-mouse IgG (1/400 in 
PBS, Dakopatts), rinsed, and finally incubated 
with a streptavidin-biotinylated horseradish 
peroxidase complex (Dakopatts). Sections were 
developed for 7 min in 3,3‘-diaminobenzidine 
tetrachloride. 
Microscopical evaluation 
Positive immunohistochemistry with the DO-7 
p53 antibody was defined as moderate or intense 
brown nuclear staining. Cytoplasmic staining 
was not found. In a semi-quantitative scoring 
approach, two staining patterns were dis- 
tinguished: a focal pattern, with >10 per cent of 
nuclei positive in clusters, was mostly found in 
non-dysplastic and low-grade dysplastic Barrett’s 
oesophagus. The focal staining was mostly con- 
fined to glandular epithelium (Fig. la). A diffuse 
staining pattern with >10 per cent of positive 
nuclei scattered through the tissue was seen in 
most adenocarcinomas and high-grade dysplasia 
(Fig. lb). 
RESULTS 
p53 labelling by standard immunohisto- 
chemistry from unfixed frozen sections of 20 
Barrett’s adenocarcinomas gave results similar 
to those obtained after the use of the antigen 
retrieval method on corresponding paraffin- 
embedded, formalin-fixed sections of these 
tumours. 
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Fig. 1-(a) Focal immunohistochemical staining of the p53 protein with the monoclonal antibody DO-7 in a paraffin-embedded 
section of a Barrett’s oesophagus biopsy with low-grade dysplasia. (b) Moderately differentiated oesophageal adenocarcinoma 
showing a diffuse immunostaining pattern of tumour cells. Both sections were counterstained by haematoxylin. A x 10 objective 
was used 
Table I-p53 immunostaining in biopsies from Barrett’s oesophagus 
Degree of 
dysplasia n 
Positive p53 
immunostaining 
No 50 3 (6%) 
High 9 8 (89%) 
Indefiniteflow 43 12 (28%) 
P<O.OOl* 
Total 102 23 (23%) 
*P value as calculated by the Trend test.2 
Normal cardia and oesophageal mucosa 
Normal cardia tissue taken from the resection 
material was used for control purposes. All 24 
cases were negative for p53. Weak nuclear staining 
with DO-7 was sporadically seen in the basal layer 
of normal squamous epithelium. 
Barvett ‘s epithelium 
Immunohistochemical assessment of biopsy 
material from 102 patients with Barrett’s epithe- 
lium without carcinoma revealed intense nuclear 
p53 staining in 23 of 102 (23 per cent) biopsies. A 
significant correlation was found between the 
grade of dysplasia and p53 staining (Trend test: 
P<O.OOl ,  Table 1). Staining for p53 was found in 8 
1 
of 9 (89 per cent) cases with high-grade dysplasia, 
12 of 43 (28 per cent) cases with indefinite or 
low-grade dysplasia, and 3 of 50 (6 per cent) cases 
of simple metaplasia (Table I). Staining was focal 
in all non-dysplastic, in eight indefiniteAow-grade 
dysplastic, and in two high-grade dysplastic cases 
(Fig. la). In ten cases, four indefiniteAow-grade 
and six high-grade, staining was diffuse. 
Barrett’s epithelium adjacent to adenocarcinoma 
Staining for p53 in Barrett’s epithelium adjacent 
to the infiltrating tumour was performed in 23 
cases. p53 staining correlated significantly with the 
grade of dysplasia (Trend test P<O-05, Table 11). 
Eight of nine (89 per cent) of the severely dysplas- 
tic cases showed diffuse staining. In 4 of 11 (36 per 
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Table 11-p53 immunostaining in Barrett’s oesophagus adjacent to adeno- 
carcinoma 
Degree of dysplasia n 
Positive p53 
immunostaining 
No 
IndefiniteAow 
High 
Total 
3 0 (OY”) 
11 4 (36%) 
9 8 (89Yo) 
23 12 (52%) 
P<0.05* 
* P  value as calculated by the Trend test.” 
Table 111-p53 immunostaining in adenocarcinomas in Barrett’s oesophagus 
Tumour stage* n 
Positive p53 
immunostainingt 
T1 
T2 
T3l4 
Total 
6 
6 
12 
6 (1 00%) 
5 (83%) 
9 (75%) 
24 20 (83%) 
*Tumour stage according to TNM classification; T1: tumour infiltration in submucosa; 
T2: tumour infiltration in muscularis propria; T3/T4: tumour infiltration in adventitia and 
beyond. 
?Focal or diffuse nuclear immunostaining. 
cent) cases with indefinite or low-grade dysplasia, 
focal p53 staining was observed. p53 immuno- 
staining was not observed in the three non- 
dysplastic epithelia adjacent to tumour. In a total 
of 11 cases of adjacent Barrett’s epithelium, p53 
immunoreactivity was not seen; four of these were 
adjacent to adenocarcinomas lacking p53 staining 
as well. 
Adenocarcinoma in Barrett ’s oesophagus 
The 24 cases of adenocarcinoma in Barrett’s 
oesophagus were distributed according to tumour 
stage as shown in Table 111. In 20 of 24 cases (83 
per cent), diffuse (19 cases) or focal (1 case) nuclear 
immunohistochemical staining for p53 was found 
(Fig. lb). Staining was similar in the three stage 
groups, with a slight preponderance of negative 
cases in the advanced tumours. No significant 
correlation was found between p53 staining and 
the grade of differentiation. 
DISCUSSION 
The study of different stages in carcinogenesis in 
a model which includes early stages of cancer 
development has important clinical implications. 
Barrett’s oesophagus might serve as a unique 
model in which early changes preceding full blown 
malignancies are encountered. Patients suffering 
from Barrett’s changes are monitored by periodic 
endoscopies and biopsies, allowing longitudinal 
follow-up studies. Although Barrett’s oesophagus 
may lead to malignancy, the course of develop- 
ment of carcinoma in the individual can hardly be 
predicted by histopathology. It is therefore of 
paramount importance to trace more objective 
parameters which are associated with dysplasia 
and which reflect the progression of malignancy. 
p53 mutation, a common genetic event in many 
human malignancie~,’-’~ might be such a par- 
ameter. Positive p53 protein immunostaining is 
generally assumed to accompany gene mutations, 
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which result in increased stability and conse- 
quent accumulation of mutated p53 protein?* 
Intense immunostaining with the DO-7 anti-p53 
antibody has proved to be highly specific for 
mutated ~ 5 3 . ~ ’  
In the present study nuclear p53 protein staining 
was shown in 23 of 102 (23 per cent) biopsies 
from Barrett’s oesophagus with different grades of 
dysplasia and in 12 of 23 (52 per cent) Barrett’s 
epithelia adjacent to tumour. In these specimens 
p53 staining correlated significantly with the 
grade of dysplasia (P<O-OOl and PCO-05, respec- 
tively), with a high prevalence (89 per cent) in 
high-grade dysplasia. The number of cases with 
nuclear p53 immunostaining in Barrett’s oesopha- 
gus in our study is somewhat higher than previ- 
ously reported.I6-l8 Differences in the applied 
monoclonal antibodies and/or in the histo- 
chemical techniques used may account for the 
discrepancies. 
Positive p53 immunostaining in Barrett’s 
oesopha us with absent or low-grade dys- 
plasia’& may indicate that p53 protein accumu- 
lation is an early event during carcinogenesis in 
Barrett’s oesophagus. Focally staining areas in 
these lesions may be associated with p53 gene 
mutations; moreover, these clones may be precur- 
sors of progressive lesions with ultimately diffuse 
p53 staining. p53 gene mutations in non-dysplastic 
and minimally dysplastic Barrett’s oesophagus 
were demonstrated by the polymerase chain reac- 
tion and sequence analysis by Casson et ~ 1 . ~ ~  
Alternatively, increased amounts of wild-type p53 
protein, resulting in positive immunostaining, were 
noticed in irradiated and highly proliferative tis- 
s u e ~ . ~ ~ * ~ ~  Since the DO-7 monoclonal antibody 
also reacts with wild-type p53 protein and since 
proliferation rates are high in Barrett’s oesopha- 
gus,’ we cannot rule out that in a subset of cases 
immunostaining was a result of immunoreaction 
of DO-7 with wild-type p53. Furthermore, using 
monoclonal antibodies, certain conditions may 
give false-negative results, such as when the 
epitope which is recognized by the DO-7 mono- 
clonal antibody is mutated or inaccessible as a 
consequence of complex formation of p53 with 
other  protein^.^' On the other hand, complete 
absence of p53 protein due to loss of both p53 
alleles, nonsense mutations, or stop codons in the 
gene would not be distinguishable from normal 
levels of wild-type p53 by immunohistochemical 
techniques; in both conditions, staining would be 
negative. 
? 
In the present study, p53 immunostaining was 
observed in 20 of 24 (83 per cent) adenocarcinomas 
in Barrett’s oesophagus. In oesophageal adenocar- 
cinomas associated with Barrett’s oesophagus, 
Younes et a1.16 reported p53 immunostaining in 7 
of 8 (87 per cent) cases. In addition, in a follow-up 
series of 24 Barrett’s oesophagus patients, three 
cases progressed to high-grade dysplasia, two of 
which had p53 immunostaining and low-grade dys- 
plasia in initial biopsy specimens.I6 In the study of 
Blount et aZ.,15 p53 immunostaining was found in 8 
of 13 (62 per cent) oesophageal adenocarcinomas, 
whereas allelic loss of the p53 gene (17p) was 
detected in 92 per cent of cases. Although we did 
not find a correlation between the tumour grade 
and p53 protein accumulation, a trend between 
increasing p53 expression with reduced tumour 
differentiation was recently seen in a larger series.” 
The absence of p53 staining in four tumours and in 
two cases of highly dysplastic Barrett’s oesophagus 
may indicate that malignant progression is possible 
without involvement of the p53 gene.28 
p53 staining in tumour and in adjacent Barrett’s 
epithelium does not necessarily correspond. In 7 of 
19 patients, Barrett’s epithelium adjacent to p53- 
positive tumour tissue showed no p53 immuno- 
staining. None of these cases showed severe 
dysplasia. A similar observation has been reported 
by Flejou et who found that p53 immuno- 
staining in Barrett’s oesophagus adjacent to p53- 
positive adenocarcinomas was only present in 
cases where the epithelium was severely dysplastic. 
Recently Hardwick et aZ.30 found positive p53 
immunostaining in ten cases of dysplastic Barrett’s 
epithelium, all adjoining p53-positive oesophageal 
adenocarcinomas. In the present study, four carci- 
nomas did not show p53 immunostaining. In all 
these cases adjacent Barrett’s epithelia, regardless 
of the degree of dysplasia, were negative as well. 
In conclusion, p53 protein accumulates in 
Barrett’s adenocarcinoma and in premalignant 
lesions, correlating with the degree of dysplasia. 
p53 immunostaining might therefore constitute a 
useful diagnostic tool. However, the predictive 
value of p53 immunostaining in biopsies without 
high-grade dysplasia should be determined in 
prospective follow-up studies. 
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